The clinicopathological significance and drug target potential of FHIT in breast cancer, a meta-analysis and literature review

References

• SiegelRNaishadhamDJemalACancer statistics, 2013CA Cancer J Clin2013631113023335087
   PubMed Web of Science ®Google Scholar
• AtalayCEpigenetics in breast cancerExp Oncol201335424624924382432
   PubMedGoogle Scholar
• WaliAFHIT: doubts are clear nowScientific World Journal2010101142115120563537
   PubMedGoogle Scholar
• SyeedNHusainSASameerASChowdhriNASiddiqiMAMutational and promoter hypermethylation status of FHIT gene in breast cancer patients of KashmirMutat Res20117071–21821095196
   PubMed Web of Science ®Google Scholar
• SzyfMDNA methylation signatures for breast cancer classification and prognosisGenome Med2012432622494847
   PubMed Web of Science ®Google Scholar
• PekarskyYPalamarchukAHuebnerKCroceCMFHIT as tumor suppressor: mechanisms and therapeutic opportunitiesCancer Biol Ther20021323223612432269
   PubMed Web of Science ®Google Scholar
• HassanMINaiyerAAhmadFFragile histidine triad protein: structure, function, and its association with tumorogenesisJ Cancer Res Clin Oncol2010136333335020033706
   PubMed Web of Science ®Google Scholar
• HuangQLiuZXieFFragile histidine triad (FHIT) suppresses proliferation and promotes apoptosis in cholangiocarcinoma cells by blocking PI3K-Akt pathwayScientific World Journal2014201417969824757411
   PubMedGoogle Scholar
• RimessiAMarchiSFotinoCIntramitochondrial calcium regulation by the FHIT gene product sensitizes to apoptosisProc Natl Acad Sci U S A200910631127531275819622739
   PubMed Web of Science ®Google Scholar
• TrapassoFPichiorriFGaspariMFhit interaction with ferredoxin reductase triggers generation of reactive oxygen species and apoptosis of cancer cellsJ Biol Chem200828320137361374418319262
   PubMed Web of Science ®Google Scholar
• IshiiHVecchioneAFongLYCancer prevention and therapy in a preclinical mouse model: impact of FHIT virusesCurr Gene Ther200441536315032614
   PubMed Web of Science ®Google Scholar
• McShaneLMAltmanDGSauerbreiWReporting recommendations for tumor marker prognostic studies (REMARK)J Natl Cancer Inst200597161180118416106022
   PubMed Web of Science ®Google Scholar
• SteelsEPaesmansMBerghmansTRole of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysisEur Respir J200118470571911716177
   PubMed Web of Science ®Google Scholar
• HigginsJPThompsonSGDeeksJJAltmanDGMeasuring inconsistency in meta-analysesBMJ2003327741455756012958120
   PubMed Web of Science ®Google Scholar
• RadpourRKohlerCHaghighiMMFanAXHolzgreveWZhongXYMethylation profiles of 22 candidate genes in breast cancer using high-throughput MALDI-TOF mass arrayOncogene200928332969297819503099
   PubMed Web of Science ®Google Scholar
• DavisNMSokoloskyMStadelmanKDeregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic interventionOncotarget20145134603465025051360
   PubMedGoogle Scholar
• KlarmannGJDeckerAFarrarWLEpigenetic gene silencing in the Wnt pathway in breast cancerEpigenetics200832596318398311
   PubMed Web of Science ®Google Scholar
• IsmailHMMedhatAMKarimAMZakharyNIMultiple Patterns of FHIT Gene Homozygous Deletion in Egyptian Breast Cancer PatientsInt J Breast Cancer2011201132594722295218
   PubMedGoogle Scholar
• StewartDJNunezMIJelinekJImpact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samplesClin Epigenetics2014611325024751
   PubMedGoogle Scholar
• DruckTHadaczekPFuTBStructure and expression of the human FHIT gene in normal and tumor cellsCancer Res19975735045129012482
   PubMed Web of Science ®Google Scholar
• BianchiFTagliabueEMenardSCampiglioMFhit expression protects against HER2–driven breast tumor development: unraveling the molecular interconnectionsCell Cycle20076664364617374991
   PubMed Web of Science ®Google Scholar
• YanagawaNOsakabeMHayashiMTamuraGMotoyamaTFrequent epigenetic silencing of the FHIT gene in penile squamous cell carcinomasVirchows Arch2008452237738218299890
   PubMedGoogle Scholar
• LeeWTAkstLMAdelsteinDJRisk factors for hypopharyngeal/upper esophageal stricture formation after concurrent chemoradiationHead Neck200628980881216732601
   PubMed Web of Science ®Google Scholar
• ZhengSMaXZhangLHypermethylation of the 5′ CpG island of the FHIT gene is associated with hyperdiploid and translocation-negative subtypes of pediatric leukemiaCancer Res20046462000200615026336
   PubMed Web of Science ®Google Scholar
• CecenerGTuncaBEgeliUThe promoter hypermethylation status of GATA6, MGMT, and FHIT in glioblastomaCell Mol Neurobiol201232223724421928112
   PubMed Web of Science ®Google Scholar
• BanzaiCNishinoKQuanJPromoter methylation of DAPK1, FHIT, MGMT, and CDKN2A genes in cervical carcinomaInt J Clin Oncol201419112713223494221
   PubMed Web of Science ®Google Scholar
• JeongYJJeongHYLeeSMBongJGParkSHOhHKPromoter methylation status of the FHIT gene and Fhit expression: association with HER2/neu status in breast cancer patientsOncol Rep20133052270227823969757
   PubMed Web of Science ®Google Scholar
• HarounRAZakharyNIMohamedMRAbdelrahmanAMKandilEIShalabyKAAssessment of the prognostic value of methylation status and expression levels of FHIT, GSTP1 and p16 in non-small cell lung cancer in Egyptian patientsAsian Pac J Cancer Prev201415104281428724935385
   PubMed Web of Science ®Google Scholar
• BeumerJHPariseRANewmanEMConcentrations of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU)Cancer Chemother Pharmacol200862236336817899082
   PubMed Web of Science ®Google Scholar
• GowherHJeltschAMechanism of inhibition of DNA methyltransferases by cytidine analogs in cancer therapyCancer Biol Ther20043111062106815539938
   PubMed Web of Science ®Google Scholar
• NewmanEMMorganRJKummarSA phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine, administered with tetrahydrouridineCancer Chemother Pharmacol201575353754625567350
   PubMed Web of Science ®Google Scholar
• ZakiSMAbdel-AzeezHAEl NagarMRMetwallyKAS AhmeedMMAnalysis of FHIT gene methylation in egyptian breast cancer women: association with clinicopathological featuresAsian Pac J Cancer Prev20151631235123925735361
   PubMedGoogle Scholar
• RaishMDhillonVSAhmadAPromoter Hypermethylation in Tumor Suppressing Genes p16 and FHIT and Their Relationship with Estrogen Receptor and Progesterone Receptor Status in Breast Cancer Patients from Northern IndiaTransl Oncol20092426427019956388
   PubMed Web of Science ®Google Scholar
• NaqviRAHussainARaishMSpecific 50′CpG island methylation signatures of FHIT and p16 genes and their potential diagnostic relevance in Indian breast cancer patientsDNA Cell Biol200827951752518593338
   PubMed Web of Science ®Google Scholar
• D ZhaoLJLiuGLiSShenABreast fragile histidine triad abnormal methylation can down-regulate the expression of its mRNA and proteinChinese Journal of Breast Disease2012 Accessed from: http://www.cqvip.com/qk/88763x/201201/41530095.html
   Google Scholar
• IliopoulosDGulerGHanSYFragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancerOncogene20052491625163315674328
   PubMed Web of Science ®Google Scholar
• YangQNakamuraMNakamuraYTwo-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancerClin Cancer Res2002892890289312231533
   PubMed Web of Science ®Google Scholar